the efficacy data, and the safety data. our fda particularly when it comes to children, are very very scrupulous in figuring out whether or not we have a benefit risk ratio that is favorable for the benefit. and it clearly came out with that. and that is the reason why they authorized it, and that is the reason why we had 14 to 0 recommendation from the advisory committee on immunization practices whose job is to look out for both the safety of the children, as well as the protection from the vaccine. so we have to get that message across to parents, and not put down or be put off by those very valid questions. we d like them to add questions, we believe we have the data to back up the answer. the vaccination for kids ages 5 to 11, obviously there are kids ages four kids younger than five, it shocked me in that respect. in some point in my life, i hope, we are not going to be
benefits outweighing the risks have to be proven. for all the reasons that dr. miesner is saying. and that may involved more involved safety studies. you know, when they did 12 to 15-year-old authorization, they did more what they call bridging trials. they bridged a lot of the data from older people to that that age group. with younger people, you are going to have to do these safety trials and and more complete data s going to need to be, you know, really accrued here. to to prove that benefit-risk ratio. i think, you know, one of the things i think, you know, is important to remember is that we look at hospitalizations. we look at deaths. but i think, one thing we have learned is that you don t want this virus. you don t want to get infected, because we don t, still, know if some of the longer-term consequences even if people who have had milder illness. that wouldn t be counted towards that severe illness. and and i am curious, along those lines, dr. miesner, when you look